Response to "absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury"

Oncologist

Volumn 13, Issue 5, 2008, Pages 613-614

  Somers, Emily C ^a   Christman, Gregory M ^a   Fisseha, Senait ^a   Marder, Wendy ^a   McCune, W Joseph ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GONADORELIN AGONIST; LEUPRORELIN;

COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; OVARY DISEASE; OVARY FUNCTION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; OVARIAN FAILURE, PREMATURE; OVARY; PROTECTIVE AGENTS; TREATMENT OUTCOME;

EID: 45749087792     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0021     Document Type: Letter

References (4)

1. Oktay K, Sönmezer M, Oktem O et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. The Oncologist 2007;12:1055-1066.
2. Clowse M, Behera M, Anders C et al. Ovarian preservation by GnRH-agonists during chemotherapy: A meta-analysis. Arthritis Rheum 2007; 56(suppl 9):S736.
3. Somers EC, Marder W, Christman GM et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-2767.
4. Hoenig J, Heisey D. The abuse of power: The pervasive fallacy of power calculations for data analysis. Am Stat 2001;55:1-6.